CN100374440C - 用于治疗肥胖的作为选择性黑色素浓缩激素受体拮抗剂的螺取代的哌啶化合物 - Google Patents

用于治疗肥胖的作为选择性黑色素浓缩激素受体拮抗剂的螺取代的哌啶化合物 Download PDF

Info

Publication number
CN100374440C
CN100374440C CNB038151936A CN03815193A CN100374440C CN 100374440 C CN100374440 C CN 100374440C CN B038151936 A CNB038151936 A CN B038151936A CN 03815193 A CN03815193 A CN 03815193A CN 100374440 C CN100374440 C CN 100374440C
Authority
CN
China
Prior art keywords
compound
alkyl
hydrogen
treatment
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038151936A
Other languages
English (en)
Chinese (zh)
Other versions
CN1665812A (zh
Inventor
D·A·布内特
W·-L·吴
T·K·萨斯库马
M·S·多马斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN1665812A publication Critical patent/CN1665812A/zh
Application granted granted Critical
Publication of CN100374440C publication Critical patent/CN100374440C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB038151936A 2002-06-27 2003-06-26 用于治疗肥胖的作为选择性黑色素浓缩激素受体拮抗剂的螺取代的哌啶化合物 Expired - Fee Related CN100374440C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39181302P 2002-06-27 2002-06-27
US60/391,813 2002-06-27

Publications (2)

Publication Number Publication Date
CN1665812A CN1665812A (zh) 2005-09-07
CN100374440C true CN100374440C (zh) 2008-03-12

Family

ID=30000757

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038151936A Expired - Fee Related CN100374440C (zh) 2002-06-27 2003-06-26 用于治疗肥胖的作为选择性黑色素浓缩激素受体拮抗剂的螺取代的哌啶化合物

Country Status (14)

Country Link
US (1) US7109207B2 (enExample)
EP (1) EP1532147B1 (enExample)
JP (1) JP4522853B2 (enExample)
CN (1) CN100374440C (enExample)
AR (1) AR040344A1 (enExample)
AT (1) ATE334983T1 (enExample)
AU (1) AU2003258957A1 (enExample)
CA (1) CA2490531C (enExample)
DE (1) DE60307289T2 (enExample)
ES (1) ES2266861T3 (enExample)
MX (1) MXPA05000185A (enExample)
PE (1) PE20040749A1 (enExample)
TW (1) TW200401777A (enExample)
WO (1) WO2004002987A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002352878B2 (en) 2001-11-27 2007-11-22 Merck Sharp & Dohme Corp. 2-Aminoquinoline compounds
AU2004209505B2 (en) 2003-02-10 2009-07-23 Banyu Pharmaceutical Co., Ltd. Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient
EP1601664B1 (en) * 2003-02-28 2008-04-30 Schering Corporation Biaryltetrahydroisoquinoline piperidines as selective mch receptor antagonists for the treatment of obesity and related disorders
WO2005092858A2 (en) 2004-03-29 2005-10-06 Pfizer Japan Inc. Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
EP1867341A4 (en) * 2005-03-29 2009-07-29 Banyu Pharma Co Ltd THERAPEUTIC AGENT FOR NON-ALCOHOLIC FATBERS AND SCREENING METHODS FOR A DRUG-RELATED BIO-TREATMENT FOR THE TREATMENT OR PREVENTION OF NON-ALCOHOLIC FATERS
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
WO2007118853A1 (en) * 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and their use as blockers of calcium channels
TW200812963A (en) * 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
EP2072519A4 (en) * 2006-09-28 2009-10-21 Banyu Pharma Co Ltd DIARYLKETIMINDERIVAT
WO2008124118A1 (en) * 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
WO2009040659A2 (en) * 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US9090084B2 (en) 2010-05-21 2015-07-28 Hewlett-Packard Development Company, L.P. Fluid ejection device including recirculation system
US9963739B2 (en) 2010-05-21 2018-05-08 Hewlett-Packard Development Company, L.P. Polymerase chain reaction systems
JP2017535545A (ja) * 2014-11-21 2017-11-30 ラボラトリオス・デル・デエレ・エステベ・エセ・ア 疼痛に対する多様な活性を有するスピロ−イソキノリン−１，４’−ピペリジン化合物
CN107312056B (zh) * 2017-08-24 2019-10-25 广西师范学院 2-(3’-羟基-17’-孕甾烷基)-5-氟苯并咪唑的合成方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001013917A1 (en) * 1999-08-26 2001-03-01 Bristol-Myers Squibb Company Npy antagonists: spiroisoquinolinone derivatives
WO2001070337A1 (en) * 2000-03-23 2001-09-27 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
US6326375B1 (en) * 1999-08-20 2001-12-04 Banyu Pharmaceutical Co., Ltd. Spiro compounds
WO2002006245A1 (en) * 2000-07-05 2002-01-24 Synaptic Pharmarceutical Corporation Selective melanin concentrating hormone-1 (mch1) receptor antagonists and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908830A (en) 1996-10-31 1999-06-01 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326375B1 (en) * 1999-08-20 2001-12-04 Banyu Pharmaceutical Co., Ltd. Spiro compounds
WO2001013917A1 (en) * 1999-08-26 2001-03-01 Bristol-Myers Squibb Company Npy antagonists: spiroisoquinolinone derivatives
WO2001070337A1 (en) * 2000-03-23 2001-09-27 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
WO2002006245A1 (en) * 2000-07-05 2002-01-24 Synaptic Pharmarceutical Corporation Selective melanin concentrating hormone-1 (mch1) receptor antagonists and uses thereof

Also Published As

Publication number Publication date
ES2266861T3 (es) 2007-03-01
PE20040749A1 (es) 2004-10-23
CA2490531C (en) 2011-03-22
DE60307289D1 (de) 2006-09-14
JP2005535641A (ja) 2005-11-24
AR040344A1 (es) 2005-03-30
US7109207B2 (en) 2006-09-19
DE60307289T2 (de) 2007-10-18
CN1665812A (zh) 2005-09-07
EP1532147A1 (en) 2005-05-25
JP4522853B2 (ja) 2010-08-11
TW200401777A (en) 2004-02-01
HK1071567A1 (en) 2005-07-22
CA2490531A1 (en) 2004-01-08
MXPA05000185A (es) 2005-04-08
WO2004002987A1 (en) 2004-01-08
US20040024002A1 (en) 2004-02-05
EP1532147B1 (en) 2006-08-02
AU2003258957A1 (en) 2004-01-19
ATE334983T1 (de) 2006-08-15

Similar Documents

Publication Publication Date Title
AU2002350269B2 (en) Piperidine -based MCH antagonists for treatment of obesity and CNS disorders
JP4335532B2 (ja) Ｍｃｈアンタゴニストおよび肥満治療でのそれらの使用
EP1532147B1 (en) Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity
JP2005507918A (ja) 肥満治療用のｍｃｈアンタゴニスト
CA2490470A1 (en) Pyrazole urea neuropeptide y y5 receptor antagonists
EP1601664B1 (en) Biaryltetrahydroisoquinoline piperidines as selective mch receptor antagonists for the treatment of obesity and related disorders
US7345042B2 (en) MCH antagonists for the treatment of obesity
EP1667679B1 (en) Aminobenzimidazoles as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders
HK1071567B (en) Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity
HK1056877B (en) Mch antagonists and their use in the treatment of obesity
AU2002244308A1 (en) MCH antagonists and their use in the treatment of obesity

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080312